Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study

Luiz E Mazzoleni; Guilherme B Sander; Eduardo A Ott; Sérgio G S Barros; Carlos F Francesconi; Carisi A Polanczyk; André C Wortmann; Alexandro L Theil; Leandro G Fritscher; Luis F Rivero; André Cartell; Maria I A Edelweiss; Diego M Uchôa; João C Prolla

doi:10.1007/s10620-006-3090-6

Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study

Dig Dis Sci. 2006 Jan;51(1):89-98. doi: 10.1007/s10620-006-3090-6.

Authors

Luiz E Mazzoleni¹, Guilherme B Sander, Eduardo A Ott, Sérgio G S Barros, Carlos F Francesconi, Carisi A Polanczyk, André C Wortmann, Alexandro L Theil, Leandro G Fritscher, Luis F Rivero, André Cartell, Maria I A Edelweiss, Diego M Uchôa, João C Prolla

Affiliation

¹ Departments of Gastroenterology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil. [email protected]

PMID: 16416218
DOI: 10.1007/s10620-006-3090-6

Abstract

Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo. A validated questionnaire assessed dyspeptic symptoms at baseline and at 3, 6, and 12 months. Endoscopies and biopsies were performed at baseline and at 3 and 12 months. There was an overall trend, although not statistically significant, for a benefit of H. pylori eradication. Of the patients in the antibiotics group, 16 of 46 (35%) had symptomatic improvement, versus 9 of 43 (21%) in the control group (P = 0.164). In a secondary analysis, it was found that of the patients without endoscopic gastric erosions, 15 of 34 (44%) in the antibiotics group and 5 of 33 (15%) of controls had symptomatic improvement (P = 0.015). Helicobacter pylori eradication did not prove to be clinically beneficial, although a tendency to symptomatic benefit was detected. Further studies are necessary to confirm the implications of endoscopic gastric erosions in these patients.

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

2-Pyridinylmethylsulfinylbenzimidazoles
Adolescent
Adult
Aged
Amoxicillin / therapeutic use*
Anti-Infective Agents / therapeutic use
Biopsy
Brazil / epidemiology
Clarithromycin / therapeutic use*
Double-Blind Method
Drug Therapy, Combination
Dyspepsia / drug therapy*
Dyspepsia / etiology
Dyspepsia / pathology
Endoscopy, Gastrointestinal
Female
Follow-Up Studies
Gastric Mucosa / microbiology
Gastric Mucosa / pathology
Gastritis / complications
Gastritis / drug therapy*
Gastritis / microbiology
Helicobacter Infections / drug therapy*
Helicobacter Infections / epidemiology
Helicobacter Infections / microbiology
Helicobacter pylori / isolation & purification*
Humans
Lansoprazole
Male
Middle Aged
Omeprazole / analogs & derivatives*
Omeprazole / therapeutic use
Prevalence
Prospective Studies
Proton Pump Inhibitors
Treatment Outcome

Substances

2-Pyridinylmethylsulfinylbenzimidazoles
Anti-Infective Agents
Proton Pump Inhibitors
Lansoprazole
Amoxicillin
Clarithromycin
Omeprazole